Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha ® (evolocumab) ...

March 13 (Reuters) - Amgen Inc said on Monday its injection Repatha significantly reduced the need for patients to undergo a procedure to reduce bad cholesterol, according to the findings of a ...

Amgen announced new data at the American Heart Association Scientific Sessions 2026 that further strengthen the case for more ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

If your doctor recently prescribed Repatha to help lower your "bad" LDL cholesterol and reduce the risk of heart disease, you may be wondering how it fits into the bigger picture of heart health.

Please provide your email address to receive an email when new articles are posted on . The product is indicated as an adjunct therapy for adults with heterozygous familial hypercholesterolemia or ...

Richard Mullvain, RPh, BCPS (AQC), CCCC, a cardiovascular clinical pharmacist and expert in cardiovascular care at the Essentia Health Heart & Vascular Center in Duluth, Minnesota, delivered a focused ...

If approved by the European Commission (EC), Repatha would be the first PCSK9 inhibitor in Europe with the option of a single monthly injection. Repatha was the first PCSK9 inhibitor to gain marketing ...

* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017 Sign up here. * Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality ...